MXPA05013900A - Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension. - Google Patents
Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension.Info
- Publication number
- MXPA05013900A MXPA05013900A MXPA05013900A MXPA05013900A MXPA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A
- Authority
- MX
- Mexico
- Prior art keywords
- stress
- brimonidine
- severity
- preventing
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion proporciona un metodo para prevenir o reducir la severidad de una condicion asociada con la tension en un sujeto administrando sistemicamente al sujeto una cantidad efectiva de brimonidina o una sal, ester, amida, estereoisomerico o mezcla racemica farmaceuticamente aceptable de la misma. Las condiciones asociadas con la tension que pueden ser tratadas de acuerdo a un metodo de la invencion incluyen, pero no se limitan a, la dispepsia, taquicardias diferentes a las taquicardias asociadas con la isquemia miocardiaca, ataque de panico, condiciones dermatologicas no inflamatorias, trastornos de la contraccion muscular, hipersensibilidad sensorial asociada con la migrana y trastornos de comportamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/607,439 US20040266776A1 (en) | 2003-06-25 | 2003-06-25 | Methods of preventing and reducing the severity of stress-associated conditions |
PCT/US2004/020194 WO2005002580A1 (en) | 2003-06-25 | 2004-06-22 | Use of brimonidine for preventing and reducing the severity of stress-associated conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05013900A true MXPA05013900A (es) | 2006-02-24 |
Family
ID=33540268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05013900A MXPA05013900A (es) | 2003-06-25 | 2004-06-22 | Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension. |
Country Status (15)
Country | Link |
---|---|
US (6) | US20040266776A1 (es) |
EP (1) | EP1638569B1 (es) |
JP (2) | JP2007524625A (es) |
KR (1) | KR20060023575A (es) |
CN (2) | CN1812791A (es) |
AT (1) | ATE539751T1 (es) |
AU (2) | AU2004253500A1 (es) |
BR (1) | BRPI0411826A (es) |
CA (1) | CA2530487C (es) |
DK (1) | DK1638569T3 (es) |
ES (1) | ES2376878T3 (es) |
HK (1) | HK1090282A1 (es) |
MX (1) | MXPA05013900A (es) |
TW (1) | TWI371276B (es) |
WO (1) | WO2005002580A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
ES2250504T3 (es) | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
NZ552325A (en) | 2004-05-25 | 2010-11-26 | Sansrosa Pharmaceutical Dev Inc | The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
WO2008144399A1 (en) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
US20090060852A1 (en) * | 2007-07-27 | 2009-03-05 | Jack Dejovin | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging |
US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
WO2009052071A1 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Treatment of sensorimotor disorders with 4- ( 1- ( 2, 3 -dimethylphenyl) ethyl) -1h-imidaz0le-2 ( 3h) -thione |
WO2009052073A2 (en) | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US8283350B2 (en) | 2008-08-01 | 2012-10-09 | Alpha Synergy Development, Inc. | Compositions and methods for reducing capillary permeability |
US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
WO2011028621A1 (en) * | 2009-08-26 | 2011-03-10 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
KR101769637B1 (ko) | 2009-11-09 | 2017-08-18 | 알러간, 인코포레이티드 | 모발 성장을 촉진하기 위한 조성물 및 방법 |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US20110152271A1 (en) * | 2009-12-17 | 2011-06-23 | Gerald Horn | Compositions and methods for ophthalmic delivery of nasal decongestants |
JP5747392B2 (ja) | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物 |
HUE033143T2 (en) | 2010-03-26 | 2017-11-28 | Galderma Res & Dev | Preparations containing brimonidine for the treatment of erythema |
US20120073515A1 (en) * | 2010-09-28 | 2012-03-29 | Advanced Bionics Corporation | Intrathecal needle guide apparatus |
RU2571277C2 (ru) | 2010-10-21 | 2015-12-20 | Галдерма С.А. | Композиции геля с бримонидином и способы применения |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
JP6092205B2 (ja) | 2011-07-14 | 2017-03-08 | アラーガン、インコーポレイテッドAllergan,Incorporated | 性的行為に関連した失禁の治療方法 |
KR20150119254A (ko) | 2013-02-15 | 2015-10-23 | 알러간, 인코포레이티드 | 지속된 약물 전달 임플란트 |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
US20170266106A1 (en) * | 2014-12-01 | 2017-09-21 | Achelios Therapeutics, Inc. | Methods and compositions for treating migraine and conditions associated with pain |
JP2021536439A (ja) * | 2018-08-29 | 2021-12-27 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 眼障害及び皮膚疾患の処置のための眼科用組成物及び方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380754A (en) * | 1988-02-29 | 1995-01-10 | Virotex Corporation | Topical composition enhancing healing of viral lesions |
JP3683908B2 (ja) * | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | (2−イミダゾリン−2−イルアミノ)キノキサリン誘導体の使用方法 |
US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6462077B1 (en) * | 1993-12-28 | 2002-10-08 | Allergan, Inc. | Thromboxane ligands without blood clotting side effects |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
WO1999030690A1 (en) | 1997-12-15 | 1999-06-24 | Axia Therapeutics, Inc. | Oral delivery formulation |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6284749B1 (en) | 1998-10-27 | 2001-09-04 | Alcon Manufacturing, Ltd. | Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap |
EP1187604A4 (en) * | 1999-05-28 | 2004-02-11 | Jeffrey Berlant | CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES |
AU5331200A (en) | 1999-06-11 | 2001-01-02 | Ohio State University Research Foundation, The | Methods and compositions for treating raynaud's phenomenon and scleroderma |
KR100331529B1 (ko) | 1999-06-16 | 2002-04-06 | 민경윤 | 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법 |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IN188750B (es) | 1999-12-04 | 2002-11-02 | Khamar Bakulesh Dr Mafatlal | |
US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
RU2311928C2 (ru) * | 2000-07-14 | 2007-12-10 | Аллерган Инк. | Композиции, содержащие альфа-2-адренергические агонисты |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
CA2468673C (en) | 2001-11-30 | 2011-01-25 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 and a3 receptors and uses thereof |
IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
NZ552325A (en) | 2004-05-25 | 2010-11-26 | Sansrosa Pharmaceutical Dev Inc | The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders |
-
2003
- 2003-06-25 US US10/607,439 patent/US20040266776A1/en not_active Abandoned
-
2004
- 2004-06-22 AU AU2004253500A patent/AU2004253500A1/en not_active Abandoned
- 2004-06-22 BR BRPI0411826-0A patent/BRPI0411826A/pt not_active IP Right Cessation
- 2004-06-22 JP JP2006517594A patent/JP2007524625A/ja active Pending
- 2004-06-22 ES ES04755981T patent/ES2376878T3/es not_active Expired - Lifetime
- 2004-06-22 EP EP04755981A patent/EP1638569B1/en not_active Expired - Lifetime
- 2004-06-22 MX MXPA05013900A patent/MXPA05013900A/es active IP Right Grant
- 2004-06-22 AT AT04755981T patent/ATE539751T1/de active
- 2004-06-22 CN CNA2004800178422A patent/CN1812791A/zh active Pending
- 2004-06-22 KR KR1020057024881A patent/KR20060023575A/ko not_active Application Discontinuation
- 2004-06-22 CN CN2011104449533A patent/CN102579448A/zh active Pending
- 2004-06-22 WO PCT/US2004/020194 patent/WO2005002580A1/en active Application Filing
- 2004-06-22 DK DK04755981.0T patent/DK1638569T3/da active
- 2004-06-22 CA CA2530487A patent/CA2530487C/en not_active Expired - Fee Related
- 2004-06-25 TW TW093118660A patent/TWI371276B/zh not_active IP Right Cessation
-
2006
- 2006-09-28 HK HK06110807.6A patent/HK1090282A1/xx not_active IP Right Cessation
-
2008
- 2008-05-02 US US12/114,719 patent/US20080207627A1/en not_active Abandoned
- 2008-05-02 US US12/114,727 patent/US7977335B2/en not_active Expired - Lifetime
-
2010
- 2010-11-18 AU AU2010241513A patent/AU2010241513B9/en not_active Ceased
-
2011
- 2011-12-13 JP JP2011272494A patent/JP2012092123A/ja active Pending
-
2012
- 2012-06-01 US US13/486,847 patent/US20120302574A1/en not_active Abandoned
- 2012-10-15 US US13/652,179 patent/US20130102612A1/en not_active Abandoned
-
2013
- 2013-02-15 US US13/768,901 patent/US20130217694A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TWI371276B (en) | 2012-09-01 |
US20130217694A1 (en) | 2013-08-22 |
US20120302574A1 (en) | 2012-11-29 |
JP2012092123A (ja) | 2012-05-17 |
US20080207627A1 (en) | 2008-08-28 |
AU2004253500A1 (en) | 2005-01-13 |
CN1812791A (zh) | 2006-08-02 |
DK1638569T3 (da) | 2012-04-02 |
US7977335B2 (en) | 2011-07-12 |
CN102579448A (zh) | 2012-07-18 |
CA2530487C (en) | 2011-11-01 |
HK1090282A1 (en) | 2006-12-22 |
WO2005002580A1 (en) | 2005-01-13 |
US20080207628A1 (en) | 2008-08-28 |
AU2010241513B9 (en) | 2011-10-20 |
US20040266776A1 (en) | 2004-12-30 |
ES2376878T3 (es) | 2012-03-20 |
KR20060023575A (ko) | 2006-03-14 |
AU2010241513B2 (en) | 2011-09-22 |
US20130102612A1 (en) | 2013-04-25 |
ATE539751T1 (de) | 2012-01-15 |
TW200524611A (en) | 2005-08-01 |
CA2530487A1 (en) | 2005-01-13 |
EP1638569B1 (en) | 2012-01-04 |
BRPI0411826A (pt) | 2006-08-08 |
AU2010241513A1 (en) | 2010-12-09 |
JP2007524625A (ja) | 2007-08-30 |
EP1638569A1 (en) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05013900A (es) | Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension. | |
WO2004108157A8 (en) | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders | |
WO2007112345A3 (en) | Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders | |
WO2005023179A3 (en) | Combination methods of treating cancer | |
WO2005047244A3 (en) | Inhibition of fgfr3 and treatment of multiple myeloma | |
WO2005092009A3 (en) | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders | |
WO2004018419A3 (en) | Benzimidazole quinolinones and uses thereof | |
WO2007112352A3 (en) | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders | |
RS69704A (en) | Treating bening prostate hyperplasia with sarms | |
WO2007129195A3 (en) | 4-pyrimidine-5-amino-pyrazole compounds | |
WO2006113498A3 (en) | 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases | |
WO2004041188A3 (en) | Compositions and methods for transdermal oxybutynin therapy | |
WO2004089353A8 (en) | Methods for treatment of parkinson's disease | |
WO2007056232A3 (en) | Methods of using saha and bortezomib for treating cancer | |
HK1107084A1 (en) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoÄ2,3-dÜpyrimidine derivatives and related compoundsfor the treatment of cancer | |
WO2008157740A3 (en) | Faah inhibitors | |
TN2011000228A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
WO2007112357A3 (en) | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders | |
WO2007022408A3 (en) | Combination methods of saha and targretin for treating cancer | |
DE602004011394D1 (en) | Thiazolderivate | |
WO2018060463A3 (en) | Treatment of prostate cancer | |
WO2007056142A3 (en) | Methods of preventing the serotonin syndrome and compositions for use therefor | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
WO2019209962A8 (en) | Compounds and uses thereof | |
MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |